📰 Device Designations News
Page 6 - Device Designations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Device Designations. Real-time updates on events, politics, business and more.
September 7, 2022
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
August 2, 2022
Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly...
August 2, 2022
Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly...
January 18, 2022
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
January 18, 2022
MONMOUTH JUNCTION, N.J., Jan. 18, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening cond...
October 7, 2021
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
January 27, 2021
Occlutechs Atrial Flow Regulator for Heart Failure Receives FDA Breakthrough Device Designation The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance. January, 27, 2021 — The U.S. Food and Drug A...
January 19, 2021
Share this article Share this article SCHAFFHAUSEN, Switzerland, Jan. 19, 2021 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the U.S Food and Drug Administration (FDA) has granted the Company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for heart failure (HF) patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction. Heart failure (HF) is a serious condition characterized by the hearts inability to pump...
December 19, 2020
Press release content from PR Newswire. The AP news staff was not involved in its creation. Occlutech’s Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation December 18, 2020 GMT SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary ...
December 18, 2020
Occlutechs Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH). PAH affects hundreds of thousands in the U.S. and globally and is resulting from change...